In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET by Hagens, MHJ et al.
RESEARCH Open Access
In vivo assessment of neuroinflammation in
progressive multiple sclerosis: a proof of
concept study with [18F]DPA714 PET
Marloes H. J. Hagens1,2* , Sandeep V. Golla3, Martijn T. Wijburg1,2, Maqsood Yaqub3, Dennis Heijtel3,4,
Martijn D. Steenwijk1,5, Patrick Schober6, John J. P. Brevé5, Robert C. Schuit3, Tristan A. Reekie7, Michael Kassiou7,
Anne-Marie van Dam1,5, Albert D. Windhorst3, Joep Killestein1,2, Frederik Barkhof1,3,8, Bart N. M. van Berckel3
and Adriaan A. Lammertsma3
Abstract
Background: Over the past decades, positron emission tomography (PET) imaging has become an increasingly
useful research modality in the field of multiple sclerosis (MS) research, as PET can visualise molecular processes,
such as neuroinflammation, in vivo. The second generation PET radioligand [18F]DPA714 binds with high affinity to
the 18-kDa translocator-protein (TSPO), which is mainly expressed on activated microglia. The aim of this proof of
concept study was to evaluate this in vivo marker of neuroinflammation in primary and secondary progressive MS.
Methods: All subjects were genotyped for the rs6971 polymorphism within the TSPO gene, and low-affinity
binders were excluded from participation in this study. Eight patients with progressive MS and seven age and
genetic binding status matched healthy controls underwent a 60 min dynamic PET scan using [18F]DPA714,
including both continuous on-line and manual arterial blood sampling to obtain metabolite-corrected arterial
plasma input functions.
Results: The optimal model for quantification of [18F]DPA714 kinetics was a reversible two-tissue compartment
model with additional blood volume parameter. For genetic high-affinity binders, a clear increase in binding
potential was observed in patients with MS compared with age-matched controls. For both high and medium
affinity binders, a further increase in binding potential was observed in T2 white matter lesions compared with
non-lesional white matter. Volume of distribution, however, did not differentiate patients from healthy controls,
as the large non-displaceable compartment of [18F]DPA714 masks its relatively small specific signal.
Conclusion: The TSPO radioligand [18F]DPA714 can reliably identify increased focal and diffuse neuroinflammation in
progressive MS when using plasma input-derived binding potential, but observed differences were predominantly
visible in high-affinity binders.
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Background
Conventional magnetic resonance imaging [1] has a central
role in the diagnosis of multiple sclerosis (MS), based on
its high sensitivity for identifying MS-specific demyelinat-
ing lesions in the brain and spinal cord [2]. In patients with
a relapsing-remitting disease course, radiological mon-
itoring is based on the development of new MS le-
sions on T2-weighted MRI and the presence of
gadolinium-enhancing lesions on T1-weighted MRI,
demonstrating disruption of the blood-brain barrier
which is indicative of active neuroinflammation [3]. How-
ever, these focal lesions as seen on MRI cannot fully ex-
plain the neurological and cognitive deficits in patients
with MS [4]. In addition, in both primary and second-
ary progressive MS, neuroinflammation usually is not
characterised by focal active demyelinating lesions [5].
Animal model and human post-mortem studies have
identified a more diffuse and low-grade neuroinflam-
mation behind an intact blood-brain barrier, not
depicted by conventional MRI [6, 7]. Consequently,
there is a need for novel imaging techniques.
Over the past decades, positron emission tomography
(PET) imaging has become an increasingly useful research
modality in the field of MS research, as PET can visualise
molecular processes, such as neuroinflammation, in vivo
[8, 9]. Specifically, the 18-kDa translocator-protein
(TSPO) receptor, which is present on the mitochondrial
membrane of microglial cells, with additional binding sites
in monocytes, astrocytes and vascular endothelium, has
shown potential as a target for imaging neuroinflamma-
tion with PET [10]. Using the first-generation TSPO PET
tracer (R)-[11C]PK11195, increased TSPO expression has
been demonstrated in both MS lesions and normal
appearing brain tissue of patients with MS, which was as-
sociated with increased disability and disease progression
in all phases of the disease [11–16]. Unfortunately, (R)-
[11C]PK11195 suffers from poor brain penetration and
high nonspecific binding in the brain, hindering accurate
quantification [12]. Over the years, a large number of
second-generation TSPO tracers have been developed,
such as [11C]PBR28, [18F]PBR111, [11C]DPA713, [18F]GE180
and [18F]FEDAA1106. These novel tracers have an
improved signal-to-noise ratio, resulting from lower lipo-
philicity and therefore less non-specific binding to e.g.
plasma proteins and improved blood-brain barrier passage
[17–21]. It has been shown that the second-generation
radioligand [18F]DPA714 provides increased bioavail-
ability to brain tissue and indeed has a higher
signal-to-noise ratio [22, 23]. One limitation of
second-generation tracers, including [18F]DPA714, is
their genetically determined binding affinity, resulting
from a single nuclide polymorphism rs6971 within the
TSPO gene. Approximately 50% of the general popula-
tion is a genetically determined high-affinity binder
(HAB), 30–40% a medium-affinity binder (MAB) and
10–20% a low-affinity binder (LAB) [24].
To date, quantification of cerebral [18F]DPA714 bind-
ing has been described in healthy controls [25] and in
patients with Alzheimer’s disease [26], with both studies
agreeing on a reversible two-tissue compartment model
with blood volume parameter (2T4k_VB) as the optimal
kinetic model. In addition, pseudo-quantitative analyses
have been performed in post-stroke [27] and Alzheimer’s
disease patients [28]. Moreover, the simplified reference
tissue model, using cerebellar grey matter as a reference
region, has been found to reliably assess binding poten-
tial in Alzheimer’s disease [26]. However, the patho-
physiology of MS violates the assumptions underlying
reference tissue models: firstly, no single brain region
can be used as a reference region in MS, as no region
can be assumed to be devoid of specific TSPO binding,
and secondly, the blood volume contribution is not neg-
ligible throughout the MS brain due to potential disrup-
tion of the blood-brain barrier [29]. The latter will also
influence the kinetics of the tracer making reference tis-
sue models unreliable [30].
The aim of this proof of concept study was to identify
the optimal plasma input tracer kinetic model for char-
acterising in vivo [18F]DPA714 kinetics in patients with
primary and secondary progressive MS and to evaluate
whether the kinetic parameters estimated from this




Patients diagnosed with primary or secondary progressive
MS, according to the 2010 revisions of the McDonald cri-
teria, and healthy controls were recruited from the MS
Center, VU University Medical Center, Amsterdam, be-
tween January 2015 and February 2016. All subjects were
genotyped for the rs6971 polymorphism within the TSPO
gene, which predicts binding affinity to the second gener-
ation TSPO tracers [24]. Only genetically high and
medium affinity binders (HAB and MAB) were included,
and genetically low-affinity binders (LAB) were excluded.
Further exclusion criteria for all subjects were a medical
history of relevant neurological or auto-immune disease
(other than MS); known cardiac, haematological, onco-
logical or renal diseases; current or previous alcohol or
drug abuse; recent treatment with immunomodulating
drugs; or the use of benzodiazepines. None of the patients
with progressive MS were on disease-modifying therapy,
and no patients were treated with intravenous methyl-
prednisolone for the last 3 months prior to the PET scans.
All subjects had normal physical examination and all
healthy controls a normal neurological examination.
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This study was approved by the Medical Ethics Review
Board of the VU University Medical Center and was reg-
istered under number 2014.356. All subjects gave written
informed consent prior to participation.
MRI acquisition
MR imaging was performed on a 3 Tesla Ingenuity TF
PET-MR system (Philips Medical Systems, Best, The
Netherlands) on the same day as the PET-CT acquisition.
MRI analysis included 3D T1 (repetition time 7.9 ms, echo
time 4.5 ms, flip angle 8°, measured voxel size 1 × 1 ×
1 mm3) for region of interest (ROI) definition and 3D T2
Fluid Attenuated Inversion Recovery (FLAIR) (repetition
time 4800 ms, echo time 279 ms, inversion time 1650 ms,
measured voxel size 0.9 × 0.9 × 1.1 mm3) for lesion seg-
mentation. In patients, additional post-contrast 2D T1 se-
quences (repetition time 600 ms, echo time 10 ms,
measured voxel size 0.56 × 0.44 × 5 mm3) were acquired.
PET acquisition and reconstruction
Radiosynthesis of [18F]DPA714 was performed with an
in-house built automatic apparatus using procedures de-
scribed previously [26]. PET scans were acquired on an In-
genuity TF PET-CT scanner (Philips Medical Systems,
Best, The Netherlands). Following a low-dose CT scan
for attenuation correction, a bolus of 263 ± 13 MBq
[18F]DPA714, with a mean molar activity of 39 ±
20 GBq/μmol, was injected intravenously at 0.8 mL/sec
with an automated infusion pump. Simultaneously, a
60-min PET dynamic emission scan was started. The
emission scan was collected in list mode and rebinned
into 19 frames (1 × 15, 3 × 5, 3 × 10, 4 × 60, 2 × 150, 2 ×
300, 4 × 600 s). PET data were reconstructed to a final
voxel size of 2 × 2 × 2 mm3 using standard scanner soft-
ware (BLOB-OS-TF), which incorporates standard correc-
tions for attenuation, scatter and randoms.
Arterial blood was withdrawn continuously from the
radial artery during the entire scan (using an automated
pump for the first 5 min at 5 mL/min and from 5 to
60 min at 2.5 mL/min), and in addition, manual samples
were collected at six time points (5, 10, 20, 30, 40 and
60 min) [31]. Continuous whole blood time activity
curves (TACs) were corrected for plasma to whole blood
ratios, metabolites and time delay to obtain metabolite-
corrected arterial plasma input functions.
Data analysis
MS white matter lesions were automatically segmented on
the FLAIR and T1-weighted images using kNN-TTP [32].
Lesion filling of the T1-weighted image was obtained
using LEAP [33], after which the filled T1-weighted image
was registered to the PET scan using the VINCI software
package [34, 35]. Grey matter, white matter and cerebral
spinal fluid segmentation was performed automatically
using SPM8 implemented in PVElab [36]. ROIs were de-
fined according to the Hammers template on the
co-registered 3D T1 MRI [37]. Regional TACs were ex-
tracted by superimposing the MR-derived ROIs onto the
dynamic PET images. Volume weighted larger ROIs were
also defined to assess the impact of ROI size on quantita-
tive analyses. The lesion masks were subtracted from seg-
mented white matter to define non-lesional white matter.
Kinetic modelling was performed using standard single-
tissue (1T2k) together with reversible and irreversible
two-tissue (2T3k and 2T4k) compartment models, both
with and without blood volume parameter (VB) [38]. It
has been hypothesised that some binding to the vascular
endothelium exists for TSPO tracers, which can be char-
acterised by slow irreversible binding (Kb) [39, 40]. There-
fore, a 2T4k_VB with an irreversible vascular binding
component (1T1k) was also tested. Akaike information
criterion (AIC) was used to compare model fits and to
identify the optimal tracer kinetic model. Reliability of par-
ameter estimates was determined by the percentage stand-
ard deviation (%SD) of these estimates, with a cut-off of
25% for the generally robust K1, and 50% for the other pa-
rameters. Estimates for K1, BPND (k3/k4), VT and Kb from
the optimal model were used to assess group differences
between patients and controls, and between genetically
high and medium affinity binders (HAB and MAB).
Statistical analysis
Group differences were evaluated using the Mann-
Whitney U test in SPSS 22.0 (IBM Corp., Armonk,
NY). Due to the explorative nature of this proof of
concept study, we did not correct for multiple com-
parisons. To evaluate regional differences within the
patient group, a Wilcoxon signed-rank test was used.
Results
Demographics
At screening, all subjects were genotyped for the rs6971
polymorphism within the TSPO gene and low-affinity
binders were excluded from participation in this study.
In total, eight patients diagnosed with primary or
secondary progressive MS and seven healthy controls
completed the whole study protocol. Demographic infor-
mation is reported in Table 1. Patients included were
four HAB and four MAB, with a mean age of 53 ± 3 years
and a wide variation in T2 lesion load, ranging from a
few solitary lesions to widespread confluent lesions (3.6
to 60.6 cm2). In only two patients, one small enhancing
lesion could be identified, not uncommon in primary or
secondary progressive MS. In healthy controls, genetic
binding status was similarly distributed: three HAB and
four MAB. The mean age for healthy controls was 52 ±
4 years, which was not significantly different from the
patients with MS (p = 0.418).
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Tracer kinetics
Based on the AIC, for the majority of subjects, the pre-
ferred model for quantification of [18F]DPA714 was
2T4k_VB_1T1k, see Fig. 1. However, when evaluating re-
liability of the parameter estimates, for a large number
of regions, K1, BPND and/or Kb could not be reliably esti-
mated, with either a high %SD or values touching the
boundaries (see Additional files 1 and 2). This was even
the case for subjects in which 2T4k_VB_1T1k was the
preferred model according to AIC, and it was true not
only for small, but also for large ROIs. As model fits for
2T4k_VB_1T1k and 2T4k_VB were comparable (see
Fig. 2) and 2T4k_VB did result in reliable parameter esti-
mates, the latter model was used for further analyses.
Volume of distribution
Mean regional VT values were on average 1.6 times
higher in HABs than in MABs (Fig. 3a). There was no
clear regional difference in VT between patients and
healthy controls for both HABs and MABs, as Fig. 3a il-
lustrates for the MS white matter lesions, non-lesional
white matter and whole brain grey matter. Moreover,
very limited within-subject variation in VT was observed,
even for the patients with MS. Figure 3b illustrates that
all subjects showed a similar distribution pattern for VT
throughout the brain. In addition, a strong correlation
between VT and K1 was seen (Fig. 4a), whereas no corre-
lations were found between VT and both k2 and k3/k4.
Finally, regional VT values for the 2T4k_VB_1T1k
model were evaluated (Fig. 3c). As expected, the added
vascular binding component decreased the VT. As the
regional VT values for the two models were strongly cor-
related for the large ROIs, there was also no difference
in 2T4k_VB_1T1k VT between patients and healthy con-
trols for both the HABs and MABs (Fig. 3c). It is of
interest to know that also the correlation between VT
and K1 as seen for the simpler model remained the same
for this model incorporating a vascular binding compo-
nent (Fig. 4b).
Binding potential
BPND (k3/k4) estimates for the larger ROIs were reli-
able using the 2T4k_VB model, as for almost all re-
gions, the standard deviation was well below 50% for
both HABs and MABs (in both patients and con-
trols), see Additional file 3. This indicates that plasma
input-derived BPND can be used as outcome param-
eter for these larger brain regions. Like VT, regional
BPND was on average 1.6 times higher in HAB than
in MAB subjects (Fig. 5). For the regions shown in
Fig. 5, this difference was statistically significant for
frontal cortex (p = 0.001), cingulate cortex (p = 0.006),
thalamic grey matter (p = 0.002) and brainstem white
matter (p = 0.004). In contrast to the VT findings, re-
gional BPND in both grey and white matter of HAB
patients was higher than in HAB healthy controls.
This difference was statistically significant for cingu-
late cortex (p = 0.034), cerebellar white matter (p =
0.034) and non-lesional white matter (p = 0.034). This
difference was not observed in the MAB group.
Multiple sclerosis lesions
In both HAB and MAB patients with MS, MRI-defined
T2 white matter lesions showed a significant increase in
BPND compared with non-lesional white matter of the
same subject (p = 0.017) (Fig. 6a). There was a strong
correlation between the BPND values, except for one pa-
tient. When including all the subjects, the correlation
coefficient (R2) was 0.246 (slope 1.04 ± 0.744), excluding





Age, mean and SD (years) 53.1 ± 2.7 52.0 ± 4.1
Gender, male/female 3/5 3/4
Genotype, HAB/MAB 4/4 3/4
Subtype MS, PPMS/SPMS 5/3 N/A
Disease duration, mean and SD (years) 13.1 ± 9.4 N/A
EDSS, median and range 5.0 (4.0–6.0) N/A
PASAT-3 score, mean and SD 45.8 ± 10.8 49.6 ± 12.5
SDMT score, mean and SD 44.0 ± 11.9 55.0 ± 13.5
T2 lesion volume, median and
range (cm3)
14.3 (3.6–60.6) N/A
Abbreviations: EDSS Expanded Disability Status Scale, HAB genetic high-affinity
binder, MAB genetic medium-affinity binder, PASAT Paced Auditory Serial
Addition Test, PPMS primary progressive multiple sclerosis, SDMT Symbol Digit
Modalities Test, SPMS secondary progressive multiple sclerosis
Fig. 1 Model preference. Number of subjects per preferred model
according to the Akaike information criterion. All subjects preferred a
reversible two-tissue compartment model (2T4k), primarily for the
model including blood volume parameter [38] and a vascular binding
component (1T1k)
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the one outlier improved the R2 to 0.861 (slope 2.39 ±
0.429). For VT, values were similar for lesions and
non-lesional white matter of each MS patient, with an
R2 of 0.844 and slope 1.02 ± 0.178 (Fig. 6b).
Discussion
This proof of concept study in patients with progressive
MS showed that quantitative assessment of the second-
generation TSPO radiotracer [18F]DPA714 can identify
an increased binding potential not only in MS-specific
lesions, but for HAB patients also in grey matter and
non-lesional white matter. Although the results from
this study need to be replicated in a larger cohort, they
suggest that [18F]DPA714-PET could be used as an in
vivo imaging technique for measuring neuroinflamma-
tion in progressive MS.
Neuroinflammation in MS is characterised by complex
and dynamic processes, including the activation of micro-
glia [6, 7]. This is most distinct in active MS lesions, iden-
tified by gadolinium enhancement on T1-weighted MRI,
and chronic MS lesions as seen on T2-weighted MRI [3].
In line with this, an increase in [18F]DPA714 BPND was
seen in the focal lesions compared with non-lesional white
matter for all patients except one, independent of the pa-
tient’s genetic binding status (HAB or MAB). As MRI-de-
fined lesions for these patients with progressive MS were
almost exclusively non-enhancing chronic lesions, this in-
crease TSPO binding indicates that these are chronic ac-
tive lesions [41]. The classification of different stages of
MS lesions, such as chronic active and chronic inactive le-
sions, results from pathological studies. Current conven-
tional MRI techniques can identify active inflammatory
lesions, with the use of gadolinium-enhanced T1-weighted
scans; however, they cannot further differentiate
non-enhancing lesions. Results from the present study
suggest that [18F]DPA714 PET can identify different stages
of MS lesions in vivo, which could be clinically relevant,
e.g. in relation to treatment options and monitoring.
Even more importantly, increased [18F]DPA714 BPND
was also seen in non-lesional brain parenchyma, both in
white and grey matter, for HAB patients. In relapsing-re-
mitting MS, neuroinflammation is evident from the de-
velopment of new focal (gadolinium enhancing) lesions,
but in primary and secondary progressive MS, neuroin-
flammation is often more diffuse and low-grade [5].
Therefore, it is highly relevant that a biomarker of neu-
roinflammation in MS demonstrates not only focal
changes, but also more diffuse pathology. As [18F]DPA714
BPND can identify both, this marker of TSPO expression
can be used as a biomarker to further investigate neuroin-
flammation in MS in vivo.
As plasma input-derived BPND was estimated reliably
using the 2T4k_VB model, BPND should be preferred
over the less specific VT. As VT contains both free,
non-specific and specific signals, it is an inferior out-
come measured compared with BPND (=k3/k4), which
only reflects specific binding. Contrary to BPND analysis,
group analysis using VT showed no difference between
patients and controls for both HAB and MAB subjects.






















































Fig. 2 Model fit comparisons. Representative model fits for the frontal
cortex of a medium affinity binding healthy control, the thalamic grey
matter of a high-affinity binding MS patient and the T2 lesions of a
medium-affinity binding MS patient. The open circles represent the
measured time-activity curves (TAC) and the solid grey and dashed
black lines represent the fits for the reversible two-tissue compartment
model without and with vascular binding component (2T4k_VB
and 2T4k_VB_1T1k)
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In addition, VT appeared to be almost similar between
different ROIs within each subject, resulting from a
nearly homogeneous distribution of DPA714 throughout
the brain of an individual. As VT includes the large non-
displaceable compartment of [18F]DPA714, this effect-
ively obscured any changes in the disease-specific neu-
roinflammatory signal. This is also seen in the analysis
of the T2 MS lesions in Fig. 6, illustrating that the in-
crease in specific [18F]DPA714 signal in MS lesions
depicted by BPND is diluted in the VT values due to the
non-displaceable component.
Interestingly, VT was strongly correlated with K1. Al-
though a change in K1 can be related to neuroinflamma-
tion, as K1 is a function of blood flow and vascular
permeability, a correlation between VT and K1 was unex-
pected as VT should be independent of K1. A possible
explanation for this finding could be related to binding
of [18F]DPA714 to the endothelium of blood vessels in
the brain [42, 43]. However, the model incorporating a
vascular binding component still provided correlated K1
and VT values (Fig. 4b).
Although the 2T4k_VB_1T1k model was preferred ac-
cording to AIC, it decreased the reliability of the param-
eter estimates compared with the simpler 2T4k_VB
model. Moreover, Kb estimates were inaccurate for many
regions, even in subjects where this model was pre-
ferred. A proposed method of decreasing the number of
parameters, attempting to increase their reliability, is fix-
ing VB to 5%. However, due to the large inter- and
intra-subject variation in VB, this seems inappropriate.
Although we used the simpler model in our analysis,
the results are similar, as the regional VT values for the
two models correlate.
In line with other TSPO studies, assessment of the
rs6971 polymorphism defined binding status is important
also for quantitative analysis of [18F]DPA714. Although
observed differences between HABs and MABs were
smaller than those observed for some other second-gener-
ation TSPO tracers [24], both mean VT and BPND values
were on average 1.6 times higher for HABs compared with
MABs for the different brain regions. This indicates that
the selection of subjects based on binding status is essen-
tial. Furthermore, group differences between HABs were
only observed when using BPND, suggesting that
[18F]DPA714 in MS could best be studied in HABs only.
Due to basal expression of TSPO, the contrast for
[18F]DPA714 appears to be too low for MAB subjects to
identify patients from controls. Strikingly, the increase in























































Fig. 3 Volume of distribution. a Volume of distribution (VT) for total grey matter non-lesional white matter (WM) and T2 defined white matter lesions
for the reversible two-tissue compartment model (2T4k_VB). High-affinity binding (HAB) subjects in red have a 1.5 to 2-fold higher VT than medium
affinity binding (MAB) subjects in blue. No difference in VT was seen between multiple sclerosis patients (MS; closed symbols) and healthy controls (HC;
open symbols) for both HABs and MABs. b VT across various regions of all patients and controls. The intra-subject variation appears to be much smaller
than the inter-subject variation. c The reversible two-tissue compartment model with vascular binding component (2T4k_VB_1T1k) also identified an
increase in VT for HAB subjects compared with MAB subjects, but no difference in mean regional VT for patients compared to controls for either HABs
or MABs
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Fig. 4 Correlation for VT and K1. For both the reversible two-tissue compartment model a without and b with vascular binding component
(2T4k_VB and 2T4k_VB_1T1k), there was a strong correlation between VT and K1 in both grey and white matter, independent of binding status





















Fig. 5 Binding potential for different regions of interest. For high-affinity binders, a higher binding potential (BPND) was seen in multiple sclerosis
patients (MS-HAB) than in healthy controls (HC-HAB) for different regions of interest. This difference was not seen in medium-affinity binding
(MAB) subjects
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BPND in MS lesions was also seen in MAB patients, indi-
cating that [18F]DPA714 can identify neuroinflammation
in MAB subjects in MS lesions, but due to high non-spe-
cific binding of the tracer, it is not evident in other ROIs
with more low-grade neuroinflammation. As only ap-
proximately half of the general population is HAB, this is
a limitation of second-generation TSPO studies.
This study is limited mainly by its small sample size.
Because of the limited number of subjects in each group,
only limited statistical analysis was performed. Neverthe-
less, based on the promising results of this pilot project,
further studies using a larger sample size are warranted.
This would allow for evaluation of possible correlations
between [18F]DPA714 BPND and clinical outcome scores,
such as Expanded Disability Status Scale and Symbol
Digit Modalities Test. Finally, assessment of a possible
relationship with MRI-derived outcome measures, such
as atrophy of cortical and deep grey matter structures,
would be of great interest in understanding progressive
MS.
Conclusions
Plasma input-derived BPND can reliably be estimated for
[18F]DPA714, and a 2T4k_VB model [
18F]DPA714 BPND
can identify increased neuroinflammation in both grey
and non-lesional white matter of patients with progres-
sive MS, with a further increase in T2 MS lesions. As
these differences cannot be seen using VT due to inclu-
sion of non-displaceable uptake, BPND is recommended
for analysis of [18F]DPA714 studies in patients with MS.
Similar to other second-generation TSPO tracers, the ef-
fect of genetically defined binding status limits the clin-
ical use of [18F]DPA714. Nevertheless, further studies
are warranted to confirm the results of the present proof
of concept study.
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Additional file 1: 2T4k_VB_1T1k - Percentage standard deviation for
BPND (k3/k4). Additional file provides the percentage of standard deviation
for the for 2T4k_VB_1T1k BPND (k3/k4) for the different large regions of
interest. (PDF 106 kb)
Additional file 2: 2T4k_VB_1T1k - Percentage standard deviation for kb.
Additional file provides the percentage of standard deviation for the for
2T4k_VB_1T1k kb for the different large regions of interest. (PDF 106 kb)
Additional file 3: 2T4k_VB - Percentage standard deviation for BPND (k3/
k4). Additional file provides the percentage of standard deviation for the
arterial input-derived BPND (k3/k4) for the different large regions of inter-
est. (PDF 106 kb)
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Fig. 6 Kinetic parameter values for the multiple sclerosis lesions. Independent of binding status, a binding potential (BPND) identified increased
[18F]DPA714 binding in MS-specific brain lesions compared with non-lesional white matter in the same patients, b whereas volume of distribution
(VT) did not depict this difference
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